BON CHARGE Unveils First-Ever Global Red Light Therapy Trend Report
BON CHARGE, a global leader in premium wellness technology, today announces the release of its inaugural Global Red Light Therapy Trend Report, showcasing how red light therapy is fast becoming a cornerstone of modern wellness routines. Based on a global survey of 7,000 adults across the U.S., UK, UAE, and Australia, the report highlights the rising adoption of red light therapy, particularly among younger consumers, with the UAE leading with seven in ten adults actively using red light therapy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122177591/en/
BON CHARGE Unveils First-Ever Global Red Light Therapy Trend Report (Photo: Business Wire)
Coinciding with the release, BON CHARGE debuts its brand refresh, including a redesigned website. This emphasizes BON CHARGE’s mission to simplify wellness by offering the world’s widest range of wellness products on a single, easy-to-access platform, empowering individuals to prioritize their self-care with science-backed technology solutions.
“As consumers become increasingly interested in their overall wellness, they are searching for accessible tools that offer multiple benefits, making red light therapy a game-changer,” said Katie Mant, Co-Founder of BON CHARGE. “Our research underscores its impact on key areas like skin appearance, sleep, and recovery, showcasing its role in shaping the future of proactive wellness worldwide.”
Red Light Therapy: A Global Trend in Wellness
The BON CHARGE Global Red Light Therapy Trend Report provides key insights into how this emerging technology is reshaping global wellness routines:
- UAE Leading the Way: Red light therapy has gained remarkable traction in the UAE, where 70% of adults report using it—far exceeding adoption rates in other markets. Nearly a third (30%) use it monthly, underscoring its popularity as a regular wellness practice.
- Younger Generations Drive Adoption: Across all surveyed markets, adults aged 18-34 are the most engaged users of red light therapy, with standout adoption rates of 77% in the UAE, 53% in the U.S. and Australia, and 46% in the UK.
- A Recent Addition to Wellness Routines: Red light therapy is still a relatively new addition for many users, with two-thirds globally reporting they started in the past two years. Younger adults (18-34) are driving this trend, with 73% of users in the UK, 70% in the UAE and 71% in the U.S. and Australia having adopted the practice recently.
- Top Device of Choice: Red light face masks lead globally as the most popular device, chosen by around a third of users (35% in the UAE, 34% in Australia, 36% in the UK and 27% in the U.S.). Note: Preferences vary by region with devices to soothe joint stiffness taking the lead in the UK and U.S. (38% and 30%, respectively).
Regional Insights Reflect Diverse Motivations
Red light therapy is a growing phenomenon. While muscle and joint relaxation is the top reason for use globally, regional nuances reveal additional motivations behind its widespread appeal:
- United Arab Emirates: The UAE sets the pace for global adoption with nearly 70% of adults engaged with red light therapy. A greater understanding of red light therapy and professional endorsements drive this trend, with 37% of users recommended by a skin specialist.
- Australia: Australians cite sleep improvement and skincare benefits as key reasons for use, after muscle and joint relaxation, and well over half (61%) have adopted red light therapy within the past two years.
- United States: Adoption is stronger among men than women in the United States, with nearly 40% reporting usage. Improved sleep and mood are cited as key motivators (28% and 24%, respectively) by users, highlighting the growing focus on recovery and mental well-being.
- United Kingdom: While adoption lags behind other markets, red light therapy is rapidly gaining traction among younger adults, with 73% of users aged 18-34 starting in the last two years. With lead motivation for use being skincare benefits, following muscle and joint relaxation.
“This report reflects a global movement toward proactive wellness,” said Andy Mant, Co-Founder of BON CHARGE. “Red light therapy’s rapid adoption, particularly among younger generations, signals a significant shift. As science continues to validate its benefits, we believe it will become as essential to wellness as nutrition and fitness.”
Explore the Full Report and Press Kit
Access the BON CHARGE Global Red Light Therapy Global Trend Report and explore key findings, visual assets, and additional resources in our digital press kit. Visit boncharge.com to download the report and learn more about BON CHARGE’s pioneering wellness solutions.
Notes to Editors
Research of 7,000 adults across the UK, USA, UAE, and Australia by Opinium Research in December 2024.
About BON CHARGE
Founded in 2017 by Katie and Andy Mant, BON CHARGE is setting new standards in simplifying wellness by offering the widest range of science-backed technology solutions to help individuals navigate their wellness journeys. The brand celebrates wellness as a continuous journey, honoring individuality and inspiring growth through community and shared knowledge. From sleep and recovery to beauty and mental well-being, BON CHARGE is a trusted partner in proactive self-care. Headquartered in Perth, Australia, every product is rooted in rigorous scientific research and designed to help individuals in achieving their wellness goals. For more information, visit boncharge.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250122177591/en/
Contacts
Press Contact
Jack Taylor PR
boncharge@jacktaylorpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pace selected by Prudential Financial to help automate its insurance operations with agentic AI4.12.2025 15:15:00 EET | Press release
Pace, the agentic workforce for insurance, was chosen by Prudential’s Individual Life Insurance (ILI) business to help simplify and improve its service delivery. Pace’s AI-powered agents are now streamlining policy servicing and supporting quality assurance efforts within Prudential’s ILI business. The first set of automated systems is now live taking on thousands of hours of work. “Our work with Prudential is an example of how AI can be used as a strategic advantage,” said Pace CEO Jamie Cuffe. “We’re thrilled to support their exceptional team with AI agents in production today that deliver best-in-class accuracy and speed at significant scale.” This multi-year agreement between Pace and Prudential’s ILI business began as a pilot and quickly moved to full production after demonstrating clear improvements in speed and operational efficiency. “We’ve taken a step forward on our journey to modernize the customer acquisition process,” said Sara Atkinson, vice president of customer acquisit
Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment4.12.2025 15:00:00 EET | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in adults with acromegaly who are currently maintained on somatostatin analogs. OXTEND-03™ is a global trial spanning approximately 75 sites across 21 countries, aiming to enroll around 120 patients. The primary goal of the trial is to confirm Debio 4126’s ability to maintain biochemical control of the disease while significantly reducing the patient’s annual treatment burden from 12 injections to just 4. This shift is expected to enhance patient convenience, improve long-term adherence, and potentially decrease healthcare resour
Visa Launches Global Art Collection to Elevate Creators and Celebrate the FIFA World Cup 26™4.12.2025 15:00:00 EET | Press release
Visa today unveiled the first five pieces in its first-ever global art collection celebrating the cultural energy of the FIFA World Cup 26™. Featuring more than twenty artists from six continents, the collection reflects Visa’s belief that creativity drives commerce—and that today’s creators are the entrepreneurs shaping communities and culture around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204080105/en/ Darien Birks (Global) Visa debuted the first five pieces in the collection at an exclusive Miami showcase, “The Art of the Draw”, hosted by multidisciplinary creator KidSuper. The showcase featured the works of artists Darien Birks, Nathan Walker, Cesar Canseco, Ivan Roque, and Rafael Mayani that celebrate the culture and traditions of each host country and host city Miami. The full collection will be unveiled globally ahead of next summer’s tournament. Commerce Meets Culture Visa will collaborate with J
Parse Biosciences Launches Evercode Whole Blood Fixation4.12.2025 15:00:00 EET | Press release
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixation of whole blood directly at the point of collection. The technology eliminates the need for on-site PBMC isolation, specialized equipment, or trained personnel, allowing translational hematology and pharmaceutical research teams to seamlessly collect blood samples in real-world clinical settings for downstream single cell analysis. Traditional single cell RNA profiling workflows done in a translational setting require a compromise between processing fresh samples, which degrade rapidly and demand skilled handling, and using fixation approaches that capture only a partial transcriptome and cannot provide paired TCR sequences. Fresh PBMC isolation also requires complex workflows and specialized reagents. Evercode Whole Blood Fixation overcomes these limitations, preserving the comprehensiv
LTIMindtree Wins Two 2025 AWS Partner Awards at AWS re:Invent4.12.2025 14:45:00 EET | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a leading global technology consulting and digital solutions provider, announced that it received the AWS 2025 Geography and Global Partner Awards, recognizing leaders around the globe who play key roles in helping clients drive innovation and build solutions on Amazon Web Services (AWS). LTIMindtree has been awarded Application Modernization Consulting Partner of the Year (Global) and Industry Partner of the Year - Travel and Hospitality. At the AWS re:Invent 2025 Partner Awards Gala, partners were recognized for their specialization, innovation, and collaboration, and for evolving business models that enable success on AWS while supporting their customers. LTIMindtree was recognized as: The Industry Partner of the Year - Travel and Hospitality: Recognized as a trusted transformation partner in Travel and Hospitality, LTIMindtree is enabling a global leader to modernize at scale—exiting global data centers and migrating seamlessly to AWS. The init
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom